Amedisys Inc (NASDAQ:AMED) COO Sells $939,305.84 in Stock
Amedisys Inc (NASDAQ:AMED) COO Christopher Gerard sold 7,892 shares of the company’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $119.02, for a total transaction of $939,305.84. Following the completion of the transaction, the chief operating officer now owns 29,429 shares of the company’s stock, valued at approximately $3,502,639.58. The sale was disclosed in a filing with the SEC, which is available at this link.
NASDAQ:AMED traded down $5.18 during trading hours on Friday, reaching $130.30. 790,161 shares of the company’s stock were exchanged, compared to its average volume of 499,023. The stock has a market cap of $4.32 billion, a P/E ratio of 58.96, a P/E/G ratio of 2.02 and a beta of 1.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a 1-year low of $49.80 and a 1-year high of $140.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.18. The firm had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. Amedisys’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. Sell-side analysts expect that Amedisys Inc will post 3.58 EPS for the current fiscal year.
Several research analysts have recently issued reports on AMED shares. Canaccord Genuity started coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. Cantor Fitzgerald started coverage on shares of Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. Bank of America set a $139.00 target price on shares of Amedisys and gave the company a “buy” rating in a report on Tuesday, September 18th. SunTrust Banks upped their target price on shares of Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday, October 11th. Finally, Robert W. Baird upped their target price on shares of Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday, October 11th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Amedisys currently has an average rating of “Buy” and a consensus price target of $107.08.
ILLEGAL ACTIVITY WARNING: “Amedisys Inc (NASDAQ:AMED) COO Sells $939,305.84 in Stock” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.mareainformativa.com/news/2018/12/08/christopher-gerard-sells-7892-shares-of-amedisys-inc-amed-stock-updated-updated-updated.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: How do candlesticks reflect price movement?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.